There were no readmissions for PE at 30 days after discharge. During the follow-up period, 43 patients (93%; 95% confidence interval, 79.3%-96.7%; P # .0001) showed improvement of RVD based on echocardiographic assessment. The modified Miller score was significantly improved from 32 6 5 to 14 6 6 at the time of hospital discharge in 42 patients (91%; P < .001). The RV:LV ratio decreased from 1.29 6 0.17 to 0.92 6 0.11 at the 1-month follow-up (P < .001). The RV function remained improved at 6 months and 1 year of follow-up, as RV:LV ratios were 0.95 6 0.14 (P < .001) and 0.93 6 0.15 (P < .001), respectively.
Objectives: This study was conducted to understand drivers of cost for carotid endarterectomy (CEA) and carotid artery stenting (CAS) and to compare variation in cost among cases performed by vascular surgery with other services.
Methods: We collected internal hospital claims data for CEA and CAS between September 2013 and August 2015 and performed a financial analysis of all hospital costs using standardized categories, including room accommodations, medications, medical and surgical supplies, imaging, and laboratory analysis. Cases were stratified by presence of symptoms and procedure type, and costs of procedures performed by vascular surgeons (VS) were compared with those performed by other services (OS).
Results: The cohort comprised 144 patients (78 asymptomatic, 66 symptomatic; 44 CAS, 100 CEA). VS (24 CAS, 70 CEA) and neurosurgery/neurointerventional radiology (20 CAS, 30 CEA) performed all procedures. Age (71 6 9 vs 70 6 11 years; P ¼ .8) and length of stay (1.7 6 2.1 vs 2.2 6 2.4 days; P ¼ .73) were similar for VS and OS. Case-mix index was similar after stratifying by symptoms (asymptomatic: 1.28 6 0.35 vs 1.39 6 0.42, P ¼ .5; symptomatic: 1.67 6 0.73 vs 1.82 6 0.81; P ¼ .9). Average hospital costs were 37% lower for asymptomatic patients. Costs were 37% higher for CAS vs CEA for asymptomatic patients and 11% higher for symptomatic patients. The largest cost components were operating room (OR) utilization, beds, and supplies, together accounting for 71% of costs. For asymptomatic CAS, average hospitalization cost was 16% less for VS compared with OS due to 44% lower OR utilization costs, 40% lower medication costs, and 78% lower intensive care unit costs. VS had 25% higher supply costs and used 16% more cardiac services. For asymptomatic CEA, average index hospitalization costs were 22% lower for VS, driven by lower utilization of OR services (28%), medications (28%), imaging (62%), and neurointerventional monitoring (64%). Symptoms were present prior to revascularization for 61%, and were more commonly treated by OS (78% vs 29%; P < .001). For symptomatic CAS, costs were similar for both groups. For symptomatic CEA, total costs were 14% lower for VS compared with OS, driven by 25% lower OR, 62% lower neurointerventional monitoring, 20% lower monitored beds, and 28% lower supply costs (and counter-balanced by 116% higher intensive care unit costs).
Conclusions: VS average hospital costs were lower for asymptomatic CAS and all CEA compared with other services. Drivers of higher cost appear to be attributed to variation in physician practice as well as patient complexity, affording an opportunity to reduce cost. Results: A total of 53 patients (68% men; mean age, 50.1 years) were treated over the study period. Indications for operation were venous thoracic outlet syndrome (n¼ 19) or CCJ stenosis associated with ipsilateral dialysis access (n ¼ 34). Eight patients underwent on-table thrombolysis for acute occlusion. All patients underwent CCJ decompression, 48 via infraclavicular first rib resection and five via claviculectomy. Five patients underwent sternoclavicular rotation for further exposure. Surgical reconstruction of the vein was used in 18 patients (34%): 9 underwent interposition grafting, 1 jugular turndown, and 8 patch angioplasty. Endovascular procedures were performed in 43 patients (81.1%): 24 underwent venous angioplasty alone, and 15 underwent stenting. Median length of stay was 4 days, with mean operative time of 135 6 63.5 minutes, and estimated blood loss of 244 6 261 mL. Perioperative complications were noted in 14 patients (26.4%) including wound complications (n ¼ 6), cardiac (n ¼ 4), reocclusion (n ¼ 3), and hemothorax requiring chest tube placement (n ¼ 1). Mean follow-up was 13.4 (0.6-58.5) months. Symptom relief was experienced in 100% of patients. During follow-up 5 patients (9.4%) developed recurrent symptoms, 6 (11.3%) reoccluded their central system, and 16 (30.2%) required reintervention for restenosis. Mean time to reintervention was 134 6 285 days. Methods: A retrospective cohort study was conducted and included all patients who underwent an open infrainguinal revascularization procedure before and after 2014. Since 2014, we have implemented strategies to reduce postoperative wound complications, among which include
